Medicus Pharma Ltd (NASDAQ:MDCX) Given Average Recommendation of “Hold” by Analysts

Shares of Medicus Pharma Ltd (NASDAQ:MDCX) have earned an average rating of “Hold” from the five brokerages that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have given a buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $9.00.

Several brokerages have recently commented on MDCX. D. Boral Capital reaffirmed a “buy” rating and set a $9.00 target price on shares of Medicus Pharma in a report on Monday, April 20th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Medicus Pharma in a research report on Wednesday, July 8th. Roth Capital initiated coverage on Medicus Pharma in a research report on Tuesday, April 21st. They set a “buy” rating for the company. Finally, Alliance Global Partners initiated coverage on Medicus Pharma in a research report on Tuesday. They issued a “buy” rating on the stock.

Institutional Investors Weigh In On Medicus Pharma

Several hedge funds have recently modified their holdings of the company. Armistice Capital LLC bought a new position in Medicus Pharma in the fourth quarter valued at about $2,771,000. Private Advisor Group LLC grew its holdings in shares of Medicus Pharma by 36.8% during the first quarter. Private Advisor Group LLC now owns 240,055 shares of the company’s stock worth $110,000 after purchasing an additional 64,560 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of Medicus Pharma during the fourth quarter worth about $92,000. HRT Financial LP bought a new position in Medicus Pharma in the 4th quarter valued at approximately $42,000. Finally, Wilmington Savings Fund Society FSB raised its holdings in Medicus Pharma by 100.0% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 51,244 shares of the company’s stock valued at $78,000 after buying an additional 25,622 shares during the last quarter.

Medicus Pharma Trading Down 7.9%

Shares of NASDAQ:MDCX traded down $0.03 during trading on Tuesday, reaching $0.29. 589,508 shares of the stock were exchanged, compared to its average volume of 3,603,806. The firm has a market cap of $16.60 million, a PE ratio of -0.11 and a beta of -0.05. Medicus Pharma has a 12 month low of $0.25 and a 12 month high of $3.05. The stock has a 50-day moving average price of $0.37 and a 200-day moving average price of $0.64.

Medicus Pharma (NASDAQ:MDCX) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.13). On average, sell-side analysts expect that Medicus Pharma will post -0.51 earnings per share for the current fiscal year.

Medicus Pharma Company Profile

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.